Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious...
Vous n'êtes pas connecté
Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to participate in a broad national effort to develop "plug-and-play" vaccines and antibody-based therapies against a wide range of emerging viruses. The grant is part of NIAID's new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network, which was announced earlier today.
Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious...
The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most...
The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most...
Researchers at the Terasaki Institute for Biomedical Innovation have been awarded a multi-million grant from the National Institutes of Health (NIH)...
Researchers at the Terasaki Institute for Biomedical Innovation have been awarded a multi-million grant from the National Institutes of Health (NIH)...
A new four-year, $3.26 million grant from the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of...
A monoclonal antibody appears effective at neutralizing the numerous variants of SARS-CoV-2, as well as related viruses in animals that could pose a...
Creative Biolabs offers a wide-ranging portfolio of antibody products designed to study key molecules associated with neurological diseases. New York,...
Creative Biolabs offers a wide-ranging portfolio of antibody products designed to study key molecules associated with neurological diseases. New York,...
Scientists at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have made a surprising finding about how antibodies...